Stock Research

Use this section to find out about a particular company or look up a term in our glossary.

GSK - GlaxoSmithKline

GSK
1,743.50
-29.62 (-1.69%)
ASK PRICE BID PRICE CHANGE
1,743.50 1,743.00 -29.62 (-1.69%)
Volume 4,908,712
Day's high 1,773.00
Day's low 1,317.50
Today’s open 1,752.50
Prev Close 1,773.00
   

Index: FTSE 100, FTSE 250, FTSE All-Share & techMARK

Sector: Pharmaceuticals & Biotechnology

  • Company URL: http://www.gsk.com
  • Company Profile: GlaxoSmithKline Plc is a healthcare conglomerate. The current company formation is the result of a merger between drug companies GlaxoWellcome and SmithKline Beecham in 2000. GSK's principal pharmaceutical products include medicines or vaccines to treat conditions including asthma, cancer, mental health, diabetes, viruses and digestive problems. Glaxo's consumer health and nutrition divisions owns such brands as Aquafresh toothpast, Panadol tablets, NiQuitin and Nicorette nicotine treatments, and Lucozade and Ribena soft drinks.

GSK Graph

Chart: 1m   3m   6m   Advanced Charting

Set GSK Alert

GSK Trade Tendency

BullBearings trader activity in the last few days with this stock

Buying: 58%

Selling: 42%

Recent trades by BullBearings members
TRADE QTY. PRICE DATE
BUY 285 1741.5p 23/05/13 12:45
BUY 84 1746p 23/05/13 12:21
SELL 575 1736.5p 23/05/13 10:36
SELL 815 1747.5p 23/05/13 08:52
SELL (auto) 1,200 1750p 23/05/13 07:16

Popular stocks in GSK's sector

Pharmaceuticals & Biotechnology
EPIC CODE ASK PRICE CHANGE  
ATD 0.60p (-23.08%) TRADE
GMX 1.00p (+46.67%) TRADE
CAT 0.96p (+2.45%) TRADE
ABH 0.06p (-9.09%) TRADE
OXB 2.40p (-3.16%) TRADE
VER 23.00p (-1.12%) TRADE
AZN 3,422.50p (-1.82%) TRADE
AKT 0.45p (-6.67%) TRADE
SHP 2,129.00p (-1.25%) TRADE
ASM 1.75p (-1.49%) TRADE
BGC 389.50p (+3.78%) TRADE

News & Reports referencing GSK

Wednesday broker round-up UPDATE

Afferro Mining: Panmure Gordon reduces target price from 279p to 100p, while keeping its buy recommendation.

Yesterday

Glaxo hit by US regulatory delay

GlaxoSmithKline has been hit by a delay to one of the six key drugs on which it was awaiting regulatory decisions this year.

3 weeks ago

Tuesday broker round-up UPDATE

Aberdeeen Asset Management: Morgan Stanley raises target price from 478p to 548p retaining an overweight rating. Bank of America ups target price from 455p to 475p and leaves its neutral rating unchanged. JP Morgan increases target price from 532p to 573p and maintains an overweight rating. Citigroup ups target price from 455p to 470p, while its neutral rating remains unchanged. UBS moves target price from 500p to 520p and retains a buy recommendation. Jefferies revises target price from 420p to 475p and keeps a hold recommendation.

3 weeks ago

GlaxoSmithKline submits application for COPD drug in EU

GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).

4 weeks ago

GSK advances on plans to sell Lucozade and Ribena brands, Q1 results disappoint

FTSE 100-listed pharmaceuticals group GlaxoSmithKline (GSK) has announced plans to sell its Lucozade and Ribena brands during its less-than-impressive first quarter results, which showed a two per cent contraction in group sales.

4 weeks ago

Traders' views

As with most currencies...”it’s all about Bernanke!”

By Ishaq Siddiqi

Earlier this week we heard from the Reserve Bank of Australia and the minutes of their meeting, which generally confirmed what most had suspected: that the strength of AUD was a pivotal factor in what was an otherwise close decision to cut interest rates.

The all-important policy guidance at the end of the minutes reveals that the RBA opted to use “some” (the “some” comment is a repeat from a couple of weeks ago) of the scope afforded by the low first quarter inflation figures and outlook, to lower the cash rate. 

A stimulus programme might be the way to go for the UK

By Christopher Beauchamp

The latest Japanese GDP reading highlights the success that the new massive stimulus programme being carried out in Japan has had in revitalising that stricken economy. Today’s drop in UK inflation suggests that the new Bank of England governor may be wise to suggest a similar policy for the UK.

The equity markets are too confident to ignore geopolitical risk and war

By Ronnie Chopra

The markets seem to be extending their highs in recent days with no concern about the continuing threat of war in the Middle East.

This morning, news that Israeli and Syrian forces have exchanged fire across the ceasefire line in the occupied Golan Heights was largely ignored by the financial markets. 

Sharp fall in silver today – fallen to levels not seen since September 2010

By Ronnie Chopra

This morning silver fell to levels not seen since September 2010 as commodity prices slumped overnight in Asia and this extended in early London trading. Although here is plenty of physical buying from China, India and the Middle East – there is heavy computer ETF selling.

A strong dollar and outperforming equity markets have shifted investor’s attention to more risky assets with silver suffering.

Has the dollar rallied too far, too quickly?

By Ishaq Siddiqi

Despite general US data thus far this week coming in a little softer, the dollar retains a bid tone, as US risk markets keep on posting new highs despite much speculation on whether USD may have rallied a little too far, too quickly.

Today we await CPI numbers and US data including housing, jobless claims and the Philly Fed.)

Trading Videos

ex Goldman Sachs Trader Tells Truth about Trading - Part 5

Morning Traders' notes

USD strengthened after Ben Bernanke's comments during Q&A session

Daily global markets overview with the overnight activity and what can be expected in the markets today. Information straight from the traders’ desks. Insights on commodities, equities, stocks and forex currencies.

Please select game...

CLOSE

Which trading game would you like to trade with ?